Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non–Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?

•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2024-09, Vol.25 (6), p.e262-e267
Hauptverfasser:	Muscolino, Paola, Scimone, Claudia, Sapuppo, Elena, Micali, Vincenzo, Vasta, Ignazio, Santacaterina, Anna, Santarpia, Mariacarmela, Russo, Alessandro
Format:	Artikel
Sprache:	eng
Schlagworte:	Acrylamides - therapeutic use Aniline Compounds - therapeutic use Antineoplastic Agents - therapeutic use C797S Carcinoma, Non-Small-Cell Lung - drug therapy Drug Resistance, Neoplasm EGFR ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Gefitinib Gefitinib - therapeutic use Humans Indoles Lung Neoplasms - drug therapy Osimertinib resistance Protein Kinase Inhibitors - therapeutic use Pyrimidines Rechallenge
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•After osimertinib resistance some patients are still sensitive to EGFR blockage.•Gefitinib rechallenge seems effective after a TKI-free interval.•Liquid biopsy can track clonal evolution of EGFR mutated NSCLCs.•Detection of EGFR mutations on ctDNA can identify patients for this strategy.
ISSN:	1525-7304 1938-0690 1938-0690
DOI:	10.1016/j.cllc.2024.06.003